Trevi Therapeutics Q1 2026 Earnings Call
Analysis based on 6 articles · First reported Apr 28, 2026 · Last updated Apr 28, 2026
The market impact is neutral as Trevi Therapeutics is conducting a routine earnings call. Investors will be looking for updates on Haduvio's clinical development and the company's financial performance, which could influence its stock price.
Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced it will host a conference call and live audio webcast on May 5, 2026. The purpose of the call is for senior management to provide a corporate update and review the company's financial results for the first quarter ended March 31, 2026. Trevi Therapeutics is developing Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The articles highlight the significant unmet medical need for these conditions in the United States.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard